CTRI/2017/11/010373Other3 期
To Evaluate the Safety and Efficacy of Sofosbuvir and Ribavirin in Patients With HCV (Genotype 3) Related Decompensated Cirrhosis - A Randomized Open- Label Study
ATCO PHARMACEUTICALS0 个研究点目标入组 62 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- Other
- 发起方
- 入组人数
- 62
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •ï?¼Male or Female >= 18 yrs
- •ï?¼Baseline HCV RNA > 1000 IU/ml
- •ï?¼Cirrhosis with current or prior decompensation
- •ï?¼HCV Genotype 3
- •ï?¼Treatment naïve or treatment experienced
排除标准
- •ï?¼HIV or HBV co-infection
- •ï?¼Recent Variceal bleed
- •ï?¼Pregnancy
- •ï?¼Haemolytic anaemia
- •ï?¼Platelet counts <20,000/ml
- •ï?¼Advanced HCC
- •ï?¼Renal dysfunction, GFR < 30 ml/min
- •ï?¼Haemoglobin < 10 g/dl
- •ï?¼MELD >25, CTP >12
- •ï?¼Post organ transplant
研究者
相似试验
招募中
2 期
?Effect of sofosbuvir/ ledipasvir on COVID-19COVID-19 pneumonia.IRCT20100228003449N29Tehran University of Medical Sciences50
已完成
3 期
Safety and efficacy of sofosbuvir in the moderate COVID19COVID19.Coronavirus infection, unspecifiedU07.1IRCT20180302038915N1Shahid Beheshti University of Medical Sciences50
招募中
2 期
Efficacy and safety of Sofosbuvir in the treatment of SARS-CoV-2: An Open Label phase II TrialSARS-CoV-2 ?associated SARI.SARS-CoV-2U07.1IRCT20200328046882N1Shahid Beheshti University of Medical Sciences60
招募中
不适用
Evaluation of the efficacy of sofosbuvir/velpatasvir and ribavirin in Japanese hepatitis C patients who failed direct-acting antiviral agents: a prospective study in real life settings.cirrhotic and non cirrhotic patients with hepatitis C virusJPRN-UMIN000035713Toranomon Hospital150
招募中
Unknown
Efficacy and Safety of sofosbuvir/velpatasvir for HCV infected patients with decompensated LCJPRN-UMIN000050343Hokkaido University Hospital50